Declaration of interest
M Maurer recently was a speaker and advisor for, and has received research funding from, Allakos, Alnylam, Aralez, AstraZeneca, Biocryst, Blueprint, CSL Behring, FAES, Genentech, Kalvista, Menarini, Novartis, Leo Pharma, Moxie, MSD, Pharming, Pharvaris, Roche, Sanofi, Shire/Takeda, UCB, and Uriach.
M Magerl was recently was a Speaker and Advisor for BioCryst, CSL Behring, KalVista, Novartis, Shire, and Pharming.
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer Disclosures
The peer reviewers have nothing to disclose.